JPRN-UMIN000046913已完成未知
Relationship between local control rate and overall survival rate in stereotactic body radiotherapy for early-stage lung cancer: systematic review - Relationship between local control rate and overall survival rate in stereotactic body radiotherapy for early-stage lung cancer: systematic review
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 13,435
研究概览
简要总结
Purpose: Local control (LC) is an important outcome of local cancer therapy, besides overall survival (OS). We conducted a comprehensive literature search to investigate whether a high LC rate contributes to good OS in radiotherapy for early-stage non-small cell lung cancer (ES-NSCLC). Conclusions: Three-year LC was correlated with three-year OS in patients receiving radiotherapy for ES-NSCLC. A 5% increase in 3-year LC is expected to improve the 3-year CSS and OS rates by 3.8% and 2.8%, respectively.
研究设计
- 研究类型
- Others,meta-analysis etc
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Articles including metastasis or articles which overall survival and local control rates are not determined on a one-to-one basis will be excluded. Studies involving patients with metastatic lung tumors, postoperative recurrence or lymph node metastases, or studies restricted to elderly patients are excluded. The reports were excluded if patients are recruited for a certain property of the tumor or patients characteristics such as pathology, ground-glass opacity, operability, or interstitial pneumonia. Data that only reported outcomes for specific patient groups (e.g., operable vs. inoperable) or tumor groups (e.g., histologically proven vs. unproven) and for which no overall outcome was given are excluded. Studies including particle therapy and concurrent chemotherapy are excluded. Concurrent chemotherapy is not permitted.
研究者
相似试验
终止
不适用
Study of a Predictor for Cervix CancerCervix CancerOncologyNCT01641484Centre Oscar Lambret9
已完成
不适用
Objective response, disease control rate, and progression-free survival, as surrogates of overall survival in trials evaluating immune checkpoint inhibitor regimens for advanced non-small cell lung cancer: individual-patient-data and study-level analysesnon-small cell lung cancerJPRN-UMIN000047001Yokohama City University Hospital3,312
Unknown
2 期
Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.Oropharyngeal NeoplasmsNCT00251381Trial Form Support S.L.90
进行中（未招募）
3 期
Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck CancerCarcinoma, Squamous Cell of Head and NeckNCT00957086National Cancer Centre, Singapore710
进行中（未招募）
不适用
Omission of Radiation in Patients With Her-2 Positive Breast CancerHER2-positive Breast CancerNCT03460067University of Kansas Medical Center12